Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis

Inclusion Criteria: * Behçet's disease (BD) patients fulfilling the International Criteria for Behçet's disease (ICBD) published in 2013 with recent recurrence of pan- or posterior uveitis * The patient should be on ≥10mg/d oral prednisone or equivalent Exclusion Criteria: * Previous treatment with TNFα inhibitors within 3 months * Pregnancy, breast feeding women * Malignancy * Heart failure * Demyelinating diseases * Renal impairment (creatinine \> 1.5 mg/dl) * Depression or other psychic disorders * History of acute or chronic inflammatory joint or autoimmune disease * Patients with severe extra-ocular involvement other than oral/genital ulcer and skin involvement * Organ or bone marrow transplant recipient, cardiac failure \> NYHA III * Acute liver disease with ALT or SGPT 2x above normal * White blood cell count \< 3500/mm\^3 * Platelet count \< 100000/mm\^3 * Hgb \< 8.5g/dl * T-SPOT TB: ≥200 SFCs per 10\^6 PBMC * Active peptic ulcer, systemic or local infection, moderate to severe osteoporosis or other contraindications of intermediate dose corticosteroids * Other severe ocular diseases or intraocular surgery within 3 months * Media opacity precluding a clear view of the fundus * Positive screen test for HBV, HCV, HIV infection or syphilis * Body weight \<45 kg * Alcohol abuse or drug abuse * Mental impairment * Uncooperative attitude